Francesco Milleri
Francesco Milleri is the President and CEO of EssilorLuxottica, a global leader in the eyewear industry. Under his leadership, the company has experienced significant growth, achieving a revenue increase of 6% to 26.5 billion euros. Milleri has been instrumental in driving innovation, particularly with the launch of new technologies such as the Nuance Audio glasses. He emphasizes the importance of research and customer feedback in creating new markets, showcasing a strong commitment to both profitability and technological advancement.
Born on Jan 01, 1958 (68 years old)
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Italy | 2 | 6.50 | 0.16% | +10% | 60,461,826 | 109,119 | $2,000,000 | 3,610$ |
| Totals | 2 | 60,461,826 | 109,119 | $2,000,000 | 3,610$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Italy:
Francesco Milleri is appreciated for his leadership and vision in the luxury market.
8
Italy:
Francesco Milleri is the president of Delfin and has been reflecting on the company's future.
5
Italy:
Francesco Milleri voted in favor of Leonardo Maria Del Vecchio's proposal during a board meeting.
5
Italy:
Francesco Milleri stated that simplifying is always a good thing during the assembly of EssilorLuxottica.
5
Italy:
Francesco Milleri's work is expressed in the execution of the will of Leonardo Del Vecchio.
6
Italy:
Francesco Milleri leads the Delfin group, which is involved in strengthening control over Mediobanca.
5
Italy:
Francesco Milleri, the head of Luxottica, is also implicated in the insider trading investigation.
2
San Marino:
Francesco Milleri is the president of Delfin involved in the case regarding Mediobanca.
5
Italy:
Francesco Milleri is also implicated in the investigation regarding Mps-Mediobanca.
4
Italy:
Francesco Milleri is the CEO of EssilorLuxottica and spoke about the company's investments in medical technology.
7